References
- Akhtar N, Ahad A, Khar RK, et al. (2011). The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin Ther Pat 21:561–76
- Bansal T, Awasthi A, Jaggi M, et al. (2008). Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. Life Sci 83:250–9
- Bansal T, Jaggi M, Khar RK, Talegaonkar S. (2009). Emerging significance of flavonoids as p-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12:46–78
- Borska S, Sopel M, Chmielewska M, et al. (2010). Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 15:857–70
- Choi JS, Piao YJ, Kang KW. (2011). Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 34:607–13
- Cohen S, Yoshiaka T, Lucarelli M. (1991). Controlled delivery system for proteins based on poly (lactic/glycolic acid) microspheres. Pharm Res 8:713–20
- Dandagi P, Patel P, Patil P, et al. (2011). Development and characterization of a particulate drug delivery system for etoposide. Indian J Novel Drug Deliv 3:43–51
- Hande KR. (1998). Clinical oncology update etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514–21
- Li X, Choi JS. (2009). Effects of quercetin on the pharmacokinetics of etoposide after oral or intravenous administration of etoposide in rats. Anticancer Res 29:1411–5
- Lo YL, Huang JD. (1999). Comparison of effects of natural or artificial rodent diet on etoposide absorption in rats. In Vivo 13:51–5
- Mainardes RM, Evangelista RC. (2005). PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 290:137–44
- Negi LM, Talegaonkar S, Jaggi M. (2013). A logical approach to optimize the nanostructured lipid carrier system of irinotecan: efficient hybrid design methodology. Nanotechnology 24:241–14
- Park J, Fong PM, Lu J, et al. (2009). PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine 5:410–8
- Shapiro AB, Ling V. (1997). Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 53:587–96
- Soma CE, Dubernet C, Bentolila D, et al. (2000). Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21:1–7
- Win KY, Feng S. (2005). Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:2713–22
- Yadav KS, Sawant KK. (2010). Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation. Curr Drug Deliv 7:51–64
- Yadav KS, Chuttani K, Mishra AK, Sawant KK. (2011). Effect of size on the biodistribution and blood clearance of etoposide-loaded PLGA nanoparticles PDA. J Pharm Sci Technol 65:131–9